BACKLIGHT
10.5.2022 17:54:12 CEST | Business Wire | Press release
Celtx, a leading media production software developer, today announced the release of Celtx Gem, the latest version of its narrative design tool for video game studios that integrates storytelling into production pipelines. Celtx Gem is powered by an entirely new purpose-built technology stack that offers video game developers the ability to architect expansive node-based narrative structures to keep pace with consumers' demand for more immersive storytelling and engaging experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005304/en/
“A typical screenplay for a two-hour feature film will have, on average, 1,000 lines of dialogue. By comparison, an immersive world video game may have more than 60,000 lines of dialogue that need to be shared with other departments such as design, cinematics, animation, production, and audio,” said Mark Kennedy, Celtx co-founder, and CEO. “Celtx Gem ensures that all teams and departments can easily collaborate at scale.”
Created in development with key partners in the video game industry, Celtx Gem adds new functionality and enhances existing features to help video game developers better manage narrative design. Product highlights include:
- Scalable platform with user-defined hierarchies keeps narrative structures organized for editing and identification.
- Rapid prototyping tools create a highly presentable interactive story map to visualize narrative structures.
- Screenplay-style editor addresses the prevalence of professional film & TV writers joining the industry by offering a familiar writing environment.
- Automated data modeling ensures that all narrative content can be easily exported and integrated with the game production pipeline.
- Logic connects with narrative design through custom conditions and variables, enabling the export of projects in open file formats commonly used in video game production.
- Collaborative tools bring together teams in a cloud-based studio for greater creativity.
“We believe Celtx and their collaborative tool is a key part of our writing pipeline and has been a strong partner supporting our development needs,” says Zac Litton, CTO for Telltale, a leading narrative game development studio and publisher.
Celtx Gem provides the technical lift to accelerate narrative design with features once reserved for in-house-developed narrative design platforms. Today, video games offer more immersive experiences and greater player agency. Video game developers now have a way to manage the large scope of narrative design and content commensurate with lengthy video game development projects.
“Today, narrative-driven AAA game development delivers immersive storytelling experiences on par with traditional entertainment like film and TV,” says Kennedy. “With Celtx Gem, we’ve paired Celtx’s robust story development and media production tools with narrative design tools in a single solution to increase creative collaboration, and help studios shorten their production pipelines.”
To learn how interactive media creators can streamline production with Celtx Gem’s narrative design tools, visit www.celtx.com/gem .
About Celtx
Celtx, a Backlight business, creates cloud-based software for the early stages of media production designed for collaborating, organizing, and producing media projects like film & TV, commercials, documentaries, games and interactive media, and podcasts. Celtx’s software is used by creatives and companies worldwide to achieve streamlined production workflows from concept to camera. For more information, visit www.celtx.com .
About Backlight
Backlight is a media technology company that dramatically improves video content ideation, production, post production and distribution. Launched in 2022 with funding from PSG, Backlight acquired media software businesses ftrack, Celtx, iconik, Wildmoka and Zype. Video-forward organizations utilize Backlight to solve their mission-critical business and operational challenges. Visit www.backlight.co for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005304/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom